Michelle Hernandez
Pediatric Allergy/Immunology · Sanford, NCNPI 1821288168
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,711 of the $25,076 with a category attached, or 62.7%. GSK accounts for 76.2% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $10,128 and has fallen 84.6% since, to $1,560 in 2025.
Across 147 payments — averaging $170.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$19K
- AstraZeneca$3K
- Alk-abello, Inc$2K
- Regeneron Healthcare Solutions, Inc.$306
- Aimmune Therapeutics, Inc.$175
- AbbVie$172
- plus $667 from 12 others
Across 64 payments — averaging $5070.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$112K
- Sanofi US Services Inc.$74K
- Pfizer$55K
- Teva Pharmaceuticals USA, Inc.$52K
- Eli Lilly$19K
- Novartis$6K
- plus $5K from 1 others
What the payments were for
- Consulting fees$15,71163%
- Speaking & faculty fees$9754%
- Travel & lodging$3,57914%
- Food & beverage$4,80319%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 65 | $19,112 |
| AstraZeneca | 26 | $2,535 |
| Alk-abello, Inc | 14 | $2,109 |
| Regeneron Healthcare Solutions, Inc. | 10 | $306 |
| Aimmune Therapeutics, Inc. | 1 | $175 |
| AbbVie(2 entities) | 3 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $148 |
| ADMA Biomanufacturing LLC | 1 | $111 |
| CSL Behring | 4 | $85 |
| Sanofi | 3 | $84 |
| Amgen | 4 | $73 |
| Novartis | 1 | $45 |
| Bio Products Laboratory USA, Inc. | 1 | $25 |
| Grifols USA, LLC | 1 | $24 |
| Sobi, Inc | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Recor Medical Inc | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few pediatric allergy/immunology providers in North Carolinato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 26 | $94,378 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $3,100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSymbicort | $2,535 | $3,10012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric allergy/immunology providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Other pediatric allergy/immunology in Sanford
- Allison BurbankSanford$6K
- Niraj PatelDurham$683K
- Talal MousallemWinston Salem$52K
- John SleasmanDurham$29K
- Puja RajaniCharlotte$4K
- Geoffrey HallDurham$2K
- Amy StallingsRaleigh$1K
- Timothy MoranChapel Hill$802
- Rebecca BuckleyDurham$238
- Teresa BrattonGreensboro$83
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.